BioMérieux Expands Point of Care Offerings with Acquisition of SpinChip

bioMérieux, a leader in in vitro diagnostics, has agreed to acquire SpinChip Diagnostics ASA, a Norwegian company known for its innovative immunoassay platform. This acquisition enhances bioMérieux's capabilities in point of care testing, offering rapid results comparable to laboratory standards. SpinChip’s technology provides test results in 10 minutes using whole blood samples, ideal for acute care settings like diagnosing myocardial infarction (MI).

SpinChip initially focuses on key cardiac markers, such as high-sensitive troponin I and NT-proBNP. The high-sensitivity assay hs-TnI has been validated and is under a European clinical trial. bioMérieux anticipates a CE marking application by end of 2025.

The acquisition is valued at €138m. With bioMérieux holding 20% of SpinChip, the remaining cash outlay will be €111m. The first product launch is slated for 2026, aligning with bioMérieux’s growth strategy and leveraging their R&D capabilities. This strategic move is expected to sustain bioMérieux's market growth beyond 2028.